Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
Chugai Pharmaceutical has re-filed a lawsuit against three Japanese generic makers over the patent of its osteoporosis treatment Edirol (eldecalcitol), this time focusing on the crystalline form, instead of the API, which was a subject of its litigation withdrawn earlier…
To read the full story
Related Article
- Chugai’s Appeal Bid for Edirol Method-of-Use Patent Dismissed
December 14, 2022
- Chugai Challenges Ruling in Method-of-Use Patent Case for Edirol
June 10, 2022
- Tokyo Court Nixes Chugai’s Method-of-Use Patent Claim for Edirol
May 30, 2022
- Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
- Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
- Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
- Chugai Drops Suit over Edirol Substance Patent, Row Continues for Method-of-Use
January 28, 2021
- Chugai Now Takes Nissan Chemical to Court over Edirol Patent, Seeks Damages from Sawai, Nichi-Iko Too
November 30, 2020
- Chugai Files Patent Litigation against Sawai, Nichi-Iko over Edirol Copies
June 1, 2020
BUSINESS
- NEC Bio, Transgene Strike Licensing Deal for Cancer Vaccine
April 6, 2026
- Expert Highlights Subcutaneous Benefits of Rybrofaz in Lung Cancer
April 6, 2026
- Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…